Plan-Les-Ouates, Switzerland

Emanuel Schmid-Siegert

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Retroviral Research by Emanuel Schmid-Siegert

Introduction

Emanuel Schmid-Siegert is a notable inventor based in Plan-Les-Ouates, Switzerland. He has made significant contributions to the field of biopharmaceutical manufacturing, particularly in the characterization and inactivation of endogenous retroviruses.

Latest Patents

Emanuel holds a patent titled "Characterization and inactivation of endogenous retroviruses in Chinese hamster ovary cells." This patent addresses the modification of Type-C endogenous retroviruses (ERVs) embedded in Chinese hamster ovary (CHO) cells to alter the release of retroviral and/or retroviral-like particles in the culture supernatant. The research identified 173 type-C ERV sequences that clustered into functionally conserved groups. Notably, the study revealed that transcripts from one type-C ERV group were full-length with intact open reading frames, leading to the presence of viral RNA genomes loaded into retroviral-like particles. The patent also discusses the disruption of the gag gene of the expressed ERV group using CRISPR-Cas9 genome editing. This innovative approach resulted in a significant reduction of viral RNA-containing particles in the cell supernatant without compromising cell growth or recombinant protein production.

Career Highlights

Emanuel Schmid-Siegert is currently associated with Selexs S.A., where he continues to advance research in the field of retroviral safety in biopharmaceuticals. His work has been pivotal in developing strategies to mitigate potential contaminations from CHO endogenous retroviruses during the manufacturing process.

Collaborations

Emanuel has collaborated with notable colleagues such as Pierre-Olivier Duroy and Sandra Bosshard, contributing to the advancement of research in their respective fields.

Conclusion

Emanuel Schmid-Siegert's innovative work in retroviral research has the potential to significantly enhance the safety of biopharmaceutical manufacturing processes. His contributions are vital for the future of this industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…